Casdatifan shows durable response linked to HIF-2α biology in kidney cancer
By
Rana R. McKay
Source
Nature CommunicationsCasdatifan shows durable response linked to HIF-2α biology in kidney cancernature.comNature, Published online: 01 July 2026; doi:10.1038/s41586-026-10718-x Monotherapy with the HIF-2α inhibitor casdatifan achieves meaningful, durable responses linked to HIF-2α biology with manageable safety in the treatment of individuals with clear cell renal cell carcinoma.
You might also wanna read
Mathematical modeling study identifies logistic model with ratio-dependent drug efficacy as best fit for NSCLC dynamics
This study evaluates which mathematical models best capture the eco-evolutionary dynamics of non-small cell lung cancer (NSCLC) by fitting t
journals.plos.org·1mo ago
Study reveals resistance mechanisms and potential treatment strategy for anaplastic thyroid cancer using type II RAF inhibitors
This study investigates resistance mechanisms to MAPK inhibition in anaplastic thyroid cancer (ATC), a highly lethal cancer. Using multi-reg
cell.com·14d ago
Protein-based pan-RAS inhibitor induces tumor regression in female mice via IFNγ and CD8+ T cell-dependent tumor necrosis
doi.org·14d ago
New Drug Shows Promise in Penetrating Pancreatic Cancer's 'Fibrotic Fortress'
Pancreatic cancer has an extremely low survival rate (97% mortality within 5 years for metastatic cases) due to late detection and the forma
sciencealert.com·25d agoExperimental Novartis radiopharma drug shows promise in early study
reut.rs·1mo ago
The immunology of human breast cancer
doi.org·14d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.